EUVIMEDEUVIMED entdecken
Multizentrische Studie

Long-Term Outcomes of Intravenous Ustekinumab Maintenance Treatment in Patients With Loss of Response to Subcutaneous Dosing

Federico Argüelles-Arias, F Javier Rodriguez González, Jaime González Antuña, Luisa Castro Laria, Fernando Gutiérrez Martinez, Guillermo Alcaín Martinez, Belén Maldonado Pérez, Raquel Camargo Camero, J Victor Martos Van Dussen, Alejandra Fernández Castañer, Teresa Valdés Delgado iD

Inflammatory Bowel Diseases · 2025

DOI: 10.1093/ibd/izae152 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Inflammatory Bowel Diseases, 2025. Verfasst von Federico Argüelles-Arias und 10 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology Department, Virgen Macarena University Hospital, Seville, Spain. Hauptthemen laut MEDLINE: Ustekinumab, Maintenance Chemotherapy, Crohn Disease, Colitis, Ulcerative. Die Arbeit nennt 15 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Ustekinumab (UST) is commonly used to treat Crohn’s disease and ulcerative colitis. However, some patients may experience diminishing response or require increased dosage. Intravenous (IV) UST maintenance is explored as a solution.

Objectives

We sought to evaluate IV UST maintenance effectiveness and safety in inflammatory bowel disease patients with partial or lost subcutaneous UST response.

Methods

This was a multicenter retrospective study of inflammatory bowel disease patients on IV UST maintenance. Clinical response and remission at weeks 12 and 52, defined as Harvey-Bradshaw Index ≤4 for Crohn’s disease or partial Mayo score ≤2 for ulcerative colitis. Objective markers reduction (fecal calprotectin, C-reactive protein), UST trough levels pre- and post-IV maintenance, and adverse events were assessed.

Results

A total of 59 patients were included. Clinical remission at weeks 12 and 52 achieved by 47.5% and 64.3% respectively. 96.6% continued IV UST at follow-up. UST serum levels quadrupled. No adverse events reported.

Conclusions

IV UST maintenance effectively sustained remission in most patients at 52 weeks.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

UstekinumabMaintenance ChemotherapyCrohn DiseaseColitis, UlcerativeHumansFemaleMaleRetrospective StudiesAdultMiddle AgedRemission InductionTreatment OutcomeC-Reactive ProteinInjections, SubcutaneousFollow-Up StudiesLeukocyte L1 Antigen ComplexAdministration, Intravenous

Stichwörter der Autor:innen

Crohn’s diseasebiologic therapyeffectivenessintravenous doselong-term outcomesustekinumab

Substanzen

UstekinumabC-Reactive ProteinLeukocyte L1 Antigen Complex

Autor:innen und Institutionen

  • Gastroenterology Department, Virgen Macarena University Hospital, Seville, Spain.
  • Department of Medicine, University of Seville, Seville, Spain.
  • Gastroenterology Department, Virgen de la Victoria University Hospital, Málaga, Spain.

ORCID-Profile: Teresa Valdés Delgado

Zitieren

APA

Argüelles-Arias, F., Rodriguez González, F. J., González Antuña, J., Castro Laria, L., Gutiérrez Martinez, F., Alcaín Martinez, G., Maldonado Pérez, B., Camargo Camero, R., Martos Van Dussen, J. V., Fernández Castañer, A., & Valdés Delgado, T. (2025). Long-Term Outcomes of Intravenous Ustekinumab Maintenance Treatment in Patients With Loss of Response to Subcutaneous Dosing. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izae152

Vancouver

Argüelles-Arias F, Rodriguez González FJ, González Antuña J, Castro Laria L, Gutiérrez Martinez F, Alcaín Martinez G, et al. Long-Term Outcomes of Intravenous Ustekinumab Maintenance Treatment in Patients With Loss of Response to Subcutaneous Dosing. Inflammatory Bowel Diseases. 2025. doi:10.1093/ibd/izae152

BibTeX
@article{ArgellesArias2025,
  author = {Argüelles-Arias, Federico and Rodriguez González, F Javier and González Antuña, Jaime and Castro Laria, Luisa and Gutiérrez Martinez, Fernando and Alcaín Martinez, Guillermo and Maldonado Pérez, Belén and Camargo Camero, Raquel and Martos Van Dussen, J Victor and Fernández Castañer, Alejandra and Valdés Delgado, Teresa},
  title = {Long-Term Outcomes of Intravenous Ustekinumab Maintenance Treatment in Patients With Loss of Response to Subcutaneous Dosing},
  journal = {Inflammatory Bowel Diseases},
  year = {2025},
  doi = {10.1093/ibd/izae152}
}
Kostenlos starten →